10 RESEARCH & DEVELOPMENT PMPA reduces viral load in HIV infection The reverse transcriptase inhibitor PMPA * is effective and well tolerated in mv infection, report researchers from the US who presented the results of their study at the 10th International Conference on Antiviral Research held in Atlanta, US, in April 1997. In this phase IIII study, patients with mv infection who had CD4+ cell counts of> 200/mm 3 were randomised to receive a single dose of IV PMPA 1 mg/kg (n = 8), PMPA 3 mg/kg (8) or placebo (4). They then received no therapy for 7 days followed by PMPA or placebo once daily for 7 days. No other antiretroviral agents were administered. Sustained response Significant decreases from baseline in HIV RNA levels occurred among PMPA recipients, while there was an increase from baseline in the mv RNA level among placebo recipients. Among PMPA 3 mg/kg recipients, the decrease in viral load was sustained for up to 1 week after the completion of therapy. No clinically significant adverse effects were associated with PMPA therapy. An oral formulation of PMPA is now under development. * Gilead Sciences; phase IIIl Gilead's PMPA significantly reduces HJV levels in phase IIII study; oral version expected to enter clinical trials soon. Business Wire [online]: [3 pages J, 14 Apr 1997. Available from: URL: hnp:llwww.newspage.com ...,,. ... Inphsrms-111 Apr 1l1li7 No. 1083 1173.8324197/1083-00010/$01.00° Adls International Limited 1l1li7. All rights reserved

PMPA reduces viral load in HIV infection

Download PDF Report

View
221
Download
4

Embed Size (px)

Citation preview

10 RESEARCH & DEVELOPMENT

PMPA reduces viral load in HIV infection

The reverse transcriptase inhibitor PMPA * is effective and well tolerated in mv infection, report researchers from the US who presented the results of their study at the 10th International Conference on Antiviral Research held in Atlanta, US, in April 1997.

In this phase IIII study, patients with mv infection who had CD4+ cell counts of> 200/mm3 were randomised to receive a single dose of IV PMPA 1 mg/kg (n = 8), PMPA 3 mg/kg (8) or placebo (4). They then received no therapy for 7 days followed by PMPA or placebo once daily for 7 days. No other antiretroviral agents were administered.

Sustained response Significant decreases from baseline in HIV RNA

levels occurred among PMPA recipients, while there was an increase from baseline in the mv RNA level among placebo recipients. Among PMPA 3 mg/kg recipients, the decrease in viral load was sustained for up to 1 week after the completion of therapy.

No clinically significant adverse effects were associated with PMPA therapy. An oral formulation of PMPA is now under development. * Gilead Sciences; phase IIIl Gilead's PMPA significantly reduces HJV levels in phase IIII study; oral version expected to enter clinical trials soon. Business Wire [online]: [3 pages J, 14 Apr 1997. Available from: URL: hnp:llwww.newspage.com ...,,. ...